Levi & Korsinsky Informs PepGen Inc. Shareholders on Lead Plaintiff Deadline for Class Action
Levi & Korsinsky, LLP has issued a notification to shareholders of PepGen Inc. regarding an important development in a class action securities lawsuit against the company. Investors have until August 8, 2025, to request that they be appointed as lead plaintiff in this case, which involves allegations of securities fraud impacting the company between March 7, 2024, and March 3, 2025.
The lawsuit aims to recover damages for investors who believe they suffered losses due to misleading statements made by PepGen Inc. regarding its lead product candidate, PGN-EDO51. Specifically, the lawsuit contends that the company misrepresented the efficacy and safety of this candidate, leading investors to have a false sense of optimism about its potential. Furthermore, it is alleged that the company’s phase two clinical trial, known as CONNECT2, was inherently flawed and not as safe as claimed.
Key claims outlined in the complaint include the following assertions:
1. PepGen Inc. misled investors about the effectiveness and safety of PGN-EDO51, directly impacting share prices negatively when the truth emerged.
2. The CONNECT2 clinical trial was deficient, raising concerns over possible FDA approval, which was not communicated adequately to investors.
3. Due to these factors, there is a substantial chance that PepGen would end the CONNECT2 study, undermining the projected commercial viability of PGN-EDO51.
Investors who experienced losses during the relevant period are strongly encouraged to assess their eligibility for participating in the lawsuit. Notably, potential lead plaintiffs are not required to incur any out-of-pocket costs, ensuring that those involved can pursue their claims without financial risk.
Levi & Korsinsky has a proven track record, with two decades of experience in securities litigation. They have successfully recovered significant amounts for shareholders in similar situations, and as a firm ranked among the top securities litigation firms in the U.S., they are well-positioned to represent the interests of aggrieved investors in this case.
If you're a shareholder of PepGen Inc. and have suffered losses, this is a vital moment to take action. To gain further insights or to initiate your claim, you may reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email or phone. An attorney from the firm will guide you through the next steps and inform you of your rights and options in this class action.
This announcement serves as a crucial reminder for PepGen Inc. investors who might be eligible to join the pending class action lawsuit. Reminders like these are vital in staying informed about rights and possible recoveries in light of securities fraud, empowering shareholders to take proactive measures concerning their investments.
For more detailed information about the case or to get in touch with the legal team, please visit the Levi & Korsinsky website or contact them directly. It's vital to act swiftly, as the deadline for lead plaintiff requests is approaching.
Background of the Case
The lawsuit aims to recover damages for investors who believe they suffered losses due to misleading statements made by PepGen Inc. regarding its lead product candidate, PGN-EDO51. Specifically, the lawsuit contends that the company misrepresented the efficacy and safety of this candidate, leading investors to have a false sense of optimism about its potential. Furthermore, it is alleged that the company’s phase two clinical trial, known as CONNECT2, was inherently flawed and not as safe as claimed.
Allegations Against PepGen
Key claims outlined in the complaint include the following assertions:
1. PepGen Inc. misled investors about the effectiveness and safety of PGN-EDO51, directly impacting share prices negatively when the truth emerged.
2. The CONNECT2 clinical trial was deficient, raising concerns over possible FDA approval, which was not communicated adequately to investors.
3. Due to these factors, there is a substantial chance that PepGen would end the CONNECT2 study, undermining the projected commercial viability of PGN-EDO51.
Investor Participation
Investors who experienced losses during the relevant period are strongly encouraged to assess their eligibility for participating in the lawsuit. Notably, potential lead plaintiffs are not required to incur any out-of-pocket costs, ensuring that those involved can pursue their claims without financial risk.
Levi & Korsinsky has a proven track record, with two decades of experience in securities litigation. They have successfully recovered significant amounts for shareholders in similar situations, and as a firm ranked among the top securities litigation firms in the U.S., they are well-positioned to represent the interests of aggrieved investors in this case.
If you're a shareholder of PepGen Inc. and have suffered losses, this is a vital moment to take action. To gain further insights or to initiate your claim, you may reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email or phone. An attorney from the firm will guide you through the next steps and inform you of your rights and options in this class action.
Conclusion
This announcement serves as a crucial reminder for PepGen Inc. investors who might be eligible to join the pending class action lawsuit. Reminders like these are vital in staying informed about rights and possible recoveries in light of securities fraud, empowering shareholders to take proactive measures concerning their investments.
For more detailed information about the case or to get in touch with the legal team, please visit the Levi & Korsinsky website or contact them directly. It's vital to act swiftly, as the deadline for lead plaintiff requests is approaching.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.